TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12823122

Group type: EXPERIMENTAL
Intervention: Educational intervention based on EuroPharm‐Forum Guidelines, provided only to the intervention group
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 119
Study: 10826131

Group type: EXPERIMENTAL
Intervention: Intravenous administration of cyanamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of cyanamide at 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of cyanamide at 1.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of cyanamide at 1.5 mg/kg
Number of subjects: 0
Study: 8953341

Group type: EXPERIMENTAL
Intervention: Female intercollegiate athletes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of nonathletic subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lean sports
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other sports
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 1834045

Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diane
Number of subjects: 20
Study: 6984828

Group type: EXPERIMENTAL
Intervention: BCG vaccine, administered as a series of four weekly intradermal injections.
Number of subjects: 44
Study: 31782747

Group type: EXPERIMENTAL
Intervention: Prescribed physical activity for five months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard treatment of care
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BMI and insulin levels correlation
Number of subjects: 84
Study: 30551317

Group type: EXPERIMENTAL
Intervention: Continuum intervention (participants listened to an interview with a person with schizophrenia who endorsed a continuum view)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Continuum intervention (participants listened to an interview with a person with schizophrenia who did not verbally broach issues of similarity to 'normal' people)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Continuum intervention (participants read a bogus research article that attested to a continuum view)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (participants read a bogus research article that was agnostic with respect to the continuum/categorical distinction)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (participants read a bogus research article that attested to a categorical view)
Number of subjects: 135
Study: 27486985

Group type: EXPERIMENTAL
Intervention: SIT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-administration of Cb with SIT
Number of subjects: 0
Study: 25280441

Group type: EXPERIMENTAL
Intervention: GNB3 C825T polymorphism T-carriers (CT/TT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: GNB3 C825T polymorphism homozygous CC group
Number of subjects: 111
Study: 22124679

Group type: EXPERIMENTAL
Intervention: Implantable 2-channel peroneal nerve stimulator
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional walking device
Number of subjects: 23
Study: 20651476

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Traditional methods of procedural teaching
Number of subjects: 53
Study: 16805120

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 30

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 30
Study: 14566442

Group type: EXPERIMENTAL
Intervention: Deramciclane (60 mg for 8 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (matched for 8 days)
Number of subjects: 16
Study: 10991864

Group type: EXPERIMENTAL
Intervention: 450 mg of VGC per os (p.o.) once a day (q.d.)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 900 mg of VGC p.o. q.d.
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1 g of oral GCV three times a day
Number of subjects: 28

Group type: COMPARATOR
Intervention: 5 mg of intravenous (i.v.) GCV per kg of body weight q.d.
Number of subjects: 28
Study: 9236310

Group type: EXPERIMENTAL
Intervention: Prophylactic oral ritodrine from the 25th to the end of the 37th week of gestation
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Hospitalization from the 28th to the 32nd week of gestation
Number of subjects: 189

Group type: COMPARATOR
Intervention: Outpatient management (control group)
Number of subjects: 189
Study: 1358620

Group type: EXPERIMENTAL
Intervention: Ebastine (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ethanol (0.8 g.kg‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ebastine with ethanol
Number of subjects: 12
Study: 6202000

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Cefotaxime and furosemide
Number of subjects: 192
Study: 30817250

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX plus Pegylated Recombinant Human Hyaluronidase (PEGPH20) at a dosage of 3 µg/kg every 2 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: FOLFIRINOX alone (Control)
Number of subjects: 138
Study: 28531768

Group type: EXPERIMENTAL
Intervention: Rosa Damascena oil (drops)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25441055

Group type: EXPERIMENTAL
Intervention: Problem-solving psychotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 46
Study: 23218058

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) training intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 71
Study: 21774293

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (TBI) with motivational interviewing and supportive techniques, individual weekly therapy sessions of 20 to 30 minutes via telephone for six weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (TBI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (received mail concerning health promotion)
Number of subjects: 60
Study: 19547854

Group type: EXPERIMENTAL
Intervention: Physical therapy in the postoperative recovery room and subsequently in the infirmary
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapy in the infirmary exclusively
Number of subjects: 0
Study: 16752186

Group type: EXPERIMENTAL
Intervention: Adiponectin concentrations in the third trimester (9.9+/‐1.4 microg/ml) compared to pregravid condition (13.5+/‐1.8 microg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin infusion in pregravid women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnancy-mediated changes in adiponectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relationship between adiponectin and insulin sensitivity
Number of subjects: 0
Study: 15180608

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no local anaesthetic)
Number of subjects: 75
Study: 11291551

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily for 10 days
Number of subjects: 148

Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 10 days
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 148
Study: 9725757

Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: oxazepam (30 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg) and oxazepam (30 mg)
Number of subjects: 30
Study: 7986772

Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined amphetamine (0.3 mg/kg) with haloperidol (2 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: Amphetamine (0.3 mg/kg)
Number of subjects: 11
Study: 2567218

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 35
Study: 5296380

Group type: EXPERIMENTAL
Intervention: Home treatment with isoniazid plus PAS
Number of subjects: 193

Group type: COMPARATOR
Intervention: Sanatorium treatment with isoniazid plus PAS
Number of subjects: 193
Study: 29625822

Group type: EXPERIMENTAL
Intervention: Culture at 36.5°C
Number of subjects: 412

Group type: COMPARATOR
Intervention: Culture at 37°C
Number of subjects: 412
Study: 27930453

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Local muscle vibration (LMV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 20
Study: 26502523

Group type: EXPERIMENTAL
Intervention: Pressing micro-regulating group
Number of subjects: 136

Group type: COMPARATOR
Intervention: Traditional massage group
Number of subjects: 136
Study: 23064079

Group type: EXPERIMENTAL
Intervention: Bupropion (75 mg twice a day for 7 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21535995

Group type: EXPERIMENTAL
Intervention: Olanzapine 5-10 mg/d
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg/d
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 18437472

Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted distal gastrectomy (LADG)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 162
Study: 17052415

Group type: EXPERIMENTAL
Intervention: Armoured laryngeal mask airway
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 100
Study: 12838221

Group type: EXPERIMENTAL
Intervention: 10F polyurethane stent
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hydrophilic hydromer‐coated polyurethane stent
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Teflon Tannenbaum stent
Number of subjects: 120
Study: 11321640

Group type: EXPERIMENTAL
Intervention: Reconstructive cognitive process
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Retrieval process
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Judged error rates
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation between judged and actual error rates
Number of subjects: 10
Study: 9256559

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Psychodynamic‐interpersonal therapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High-impact sessions
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low-impact sessions
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Therapists' ratings of session depth and smoothness
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clients' ratings of mood
Number of subjects: 57
Study: 8290661

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150-200 mg/day
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Venlafaxine 50-75 mg/day
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg/day
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 3069486

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no Nifedipine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 20
Study: 29202886

Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Neither therapy
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Discharge home
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Symptomatic on arrival
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Factors associated with rhythm control
Number of subjects: 2609
Study: 28166751

Group type: EXPERIMENTAL
Intervention: Paper-based educational intervention providing specific information about guideline recommendations for surveillance colonoscopy.
Number of subjects: 767

Group type: COMPARATOR
Intervention: Generic pamphlet on colorectal cancer treatment (Control group).
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Overall adherence to new guidelines (post hoc analysis).
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Overall adherence to old guidelines (post hoc analysis).
Number of subjects: 767
Study: 24467843

Group type: EXPERIMENTAL
Intervention: High velocity, low amplitude (HVLA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mobilization (Mob)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glide (SNAG)
Number of subjects: 51
Study: 22545990

Group type: EXPERIMENTAL
Intervention: Self-managed loaded exercise programme
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual clinic-based physiotherapy
Number of subjects: 210
Study: 19891671

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 32

Group type: COMPARATOR
Intervention: classic laryngeal mask airway
Number of subjects: 32
Study: 17637601

Group type: EXPERIMENTAL
Intervention: Juice
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fresh fruit
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dried fruit
Number of subjects: 14
Study: 16245914

Group type: EXPERIMENTAL
Intervention: Shenmai injection
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (western medicine only)
Number of subjects: 65
Study: 12044376

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous fluids in accordance with hospital practice (> or = 3 L water and 154 mmol sodium per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Restricted intake (< or = 2 L water and 77 mmol sodium per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous fluids in accordance with hospital practice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Restricted intake
Number of subjects: 20
Study: 9862566

Group type: EXPERIMENTAL
Intervention: Marked infiltration of dendritic cells (DCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slight infiltration of dendritic cells (DCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infiltration by dendritic cells (DCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expression of vascular endothelial growth factor (VEGF)
Number of subjects: 0
Study: 7616473

Group type: EXPERIMENTAL
Intervention: Irradiated polyglactin 910
Number of subjects: 236

Group type: COMPARATOR
Intervention: Traditional interrupted, monofilament, non-absorbable suturing (Control)
Number of subjects: 236
Study: 2665554

Group type: EXPERIMENTAL
Intervention: 1.7 g/kg alcohol drink on Days 1-4, placebo on Day 5
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo drink on all study Days (1-5)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol stimuli
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water or pepper juice stimuli
Number of subjects: 24
Study: 627302

Group type: EXPERIMENTAL
Intervention: Floctafenine (Idarac) 200 mg four times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen 200 mg four times daily
Number of subjects: 0
Study: 31812785

Group type: EXPERIMENTAL
Intervention: Simulation-based learning (SBL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 70
Study: 30430592

Group type: EXPERIMENTAL
Intervention: 20-week Physical Activity Program
Number of subjects: 0
Study: 28454795

Group type: EXPERIMENTAL
Intervention: Combo sirolimus‐eluting stent
Number of subjects: 572

Group type: COMPARATOR
Intervention: Best-in-class contemporary everolimus‐eluting stent
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve assessment
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography imaging
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Serial human antimurine antibody assessments
Number of subjects: 572
Study: 25841317

Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No additional treatment (non-CXL)
Number of subjects: 13
Study: 23544117

Group type: EXPERIMENTAL
Intervention: Music education intervention (n=114)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (n=121)
Number of subjects: 235
Study: 21861333

Group type: EXPERIMENTAL
Intervention: Shochu with meal (460 kcal)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Shochu without meal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Beer with meal (460 kcal)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Beer without meal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Shochu in prandial condition
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Shochu in fasted condition
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Beer in prandial condition
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Beer in fasted condition
Number of subjects: 35
Study: 19571762

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (18 ml of 0.25% bupivacaine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined superficial and deep cervical plexus block (14 ml superficial + 4 ml deep of 0.25% bupivacaine)
Number of subjects: 90
Study: 17268410

Group type: EXPERIMENTAL
Intervention: 5 g/day inulin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8 g/day inulin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 8 g/day)
Number of subjects: 30
Study: 16888425

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12716777

Group type: EXPERIMENTAL
Intervention: murabutide 7 mg/day on five consecutive days/week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no murabutide)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: murabutide 7 mg/day
Number of subjects: 42
Study: 10640054

Group type: EXPERIMENTAL
Intervention: Early discharge with home health care (postoperative day 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard discharge (a day or more later without home health care)
Number of subjects: 0
Study: 7483792

Group type: EXPERIMENTAL
Intervention: TBE vaccine on days 0 and 28
Number of subjects: 121

Group type: COMPARATOR
Intervention: TBE vaccine plus TBE immunoglobulin on day 0 plus TBE vaccine on day 28
Number of subjects: 121
Study: 1836920

Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 108
Study: 6123342

Group type: EXPERIMENTAL
Intervention: Doxazosin (12 micrograms/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Prazosin (not specified dosage)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 6
Study: 31876967

Group type: EXPERIMENTAL
Intervention: 1-day training in the RNR model of offending behavior (n=36)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wait-list control condition (n=23)
Number of subjects: 59
Study: 31362591

Group type: COMPARATOR
Intervention: Lowest-income sites (quintile 1)
Number of subjects: 27862
Study: 28478732

Group type: EXPERIMENTAL
Intervention: Magnetic DJ (Blackstar, Urotech)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard DJ
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Magnetic DJ
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cystoscopic DJ
Number of subjects: 60
Study: 25262388

Group type: EXPERIMENTAL
Intervention: water of the 3 sulfates
Number of subjects: 50

Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 50
Study: 23819698

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg twice daily
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study: 21674132

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation with warfarin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mean blood pressure
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antiplatelet agents (aspirin or thienopyridine)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Therapeutic INR range
Number of subjects: 50
Study: 18095748

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study: 16154543

Group type: EXPERIMENTAL
Intervention: PTSD group (12 police officers with PTSD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (12 traumatized police officers without lifetime PTSD)
Number of subjects: 24
Study: 12546741

Group type: EXPERIMENTAL
Intervention: Steroid treatment (hydrocortisone sodium succinate at 150 mg to 200 mg daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional supporting treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Steroid treatment (hydrocortisone sodium succinate)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 120
Study: 10732889

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1462
Study: 8883116

Group type: EXPERIMENTAL
Intervention: Alfacalcidol treatment (0.25 micrograms twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vitamin D2 supplementation (500‐1000 units daily)
Number of subjects: 46
Study: 1396893

Group type: EXPERIMENTAL
Intervention: Restricted fluid intake until 4 weeks of age
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional fluid regimen used in the hospital
Number of subjects: 100
Study: 3919550

Group type: EXPERIMENTAL
Intervention: Molsidomine (8 to 12 mg orally)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Molsidomine (8 to 12 mg intravenously)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Molsidomine (12 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Molsidomine (12 mg intravenously)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nitroglycerin (1.6 mg sublingually)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Molsidomine and Nitroglycerin
Number of subjects: 48